2026-05-28T08:42:16Zhttps://riuma.uma.es/rest/oai/requestoai:riuma.uma.es:10630/400232026-02-03T11:24:16Zcom_10630_2254col_10630_37953
RIUMA. Repositorio Institucional de la Universidad de Málaga
author
Moreno Carrasco, Gloria
author
Ortiz-Flores, Rodolfo
author
García Delgado, Regina
author
Cidoncha Morcillo, Borja
author
Rosell-Mas, Ana Isabel
author
Díaz Canales, Dana
author
Rodríguez-González, María
author
Carrasco Gomariz, Manuel
author
Escamilla-Sánchez, Alejandro
2025-09-25T08:33:12Z
2025-09-25T08:33:12Z
2025
Carrasco GM, Flores RMO, Delgado RG, Morcillo BC, Rosell Mas AI, Díaz Canales D, González MR, Gomariz MC, Escamilla-Sánchez A. Impact of Pre-Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis. Cancer Med. 2025 Aug;14(15):e71127. doi: 10.1002/cam4.71127. PMID: 40755125; PMCID: PMC12319231.
https://hdl.handle.net/10630/40023
10.1002/cam4.71127
Background: Myelodysplastic syndromes (MDS) encompass a heterogeneous group of haematological neoplasms characterized
by ineffective haematopoiesis and a variable risk of transformation to acute myeloid leukaemia (AML). Elevated serum ferritin
(SF), a marker of iron overload (IO), has been linked to poorer outcomes in MDS. However, the impact of pre-treatment SF levels
on azacytidine (AZA) response and survival outcomes remains unclear.
Methods: This retrospective cohort study included patients with World Health Organization- defined MDS or AML with
20%–30% bone marrow blasts treated with AZA at the Virgen de la Victoria University Hospital (Málaga, Spain) from 2007
onwards. Patients were stratified into three groups based on pre-treatment SF levels: < 500 ng/mL, 500–1000 ng/mL and
> 1000 ng/mL. Logistic regression and Kaplan–Meier methods were used to analyse overall response (OR) and overall sur-
vival (OS).
Results: Among 240 patients, 190 with available SF data were analysed. Patients with SF > 1000 ng/mL showed significantly
lower OR (24.2%) and shorter OS (median: 10.1 months) compared to those with SF < 500 ng/mL (OR: 71.4%, OS: 18.2 months)
and 500–1000 ng/mL (OR: 82.6%, OS: 20.5 months) (p < 0.0001 for OR, p = 0.001 for OS). Multivariate analysis confirmed elevated
SF as an independent predictor of poorer outcomes.
Conclusions: Elevated pre-treatment SF levels are strongly associated with reduced response and survival in patients with MDS
or AML treated with AZA. Early IO management, such as iron chelation, may improve treatment outcomes.
eng
Atribución 4.0 Internacional
Síndromes mielodisplásicos
Marcadores bioquímicos
Supervivencia
Pronóstico médico
Impact of Pre-Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis
journal article
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
URL
https://riuma.uma.es/bitstreams/9020df84-755d-4e89-a789-bd057009a127/download
File
MD5
209e0ff7dabe9d08364c67ac3752bd0e
436211
application/pdf
Cancer Medicine - 2025 - Carrasco - Impact of Pre‐Treatment Serum Ferritin on Response and Survival in Myelodysplastic.pdf